Medincell (XPAR:MEDCL) Change In Inventory : €-2.90 Mil (TTM As of Sep. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Medincell Change In Inventory?

Medincell's change in inventory for the quarter that ended in Sep. 2023 was €-2.14 Mil. It means Medincell's inventory increased by €2.14 Mil from Mar. 2023 to Sep. 2023 .

Medincell's change in inventory for the fiscal year that ended in Mar. 2023 was €0.00 Mil. It means Medincell's inventory stayed the same from Mar. 2022 to Mar. 2023 .

Medincell's Total Inventories for the quarter that ended in Sep. 2023 was €0.00 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Medincell's Inventory-to-Revenue for the quarter that ended in Sep. 2023 was 0.00.

Medincell Change In Inventory Historical Data

The historical data trend for Medincell's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medincell Change In Inventory Chart

Medincell Annual Data

Trend

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Change In Inventory

Get a 7-Day Free Trial

0.06

Medincell Semi-Annual Data
	Mar16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
Change In Inventory	Get a 7-Day Free Trial										-	-	0.76	-0.76	-2.14

Medincell Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Sep. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-2.90 Mil.

Medincell (XPAR:MEDCL) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Medincell's Days Inventory for the quarter that ended in is calculated as:

Days Inventory	=	Average Total Inventories	/	Cost of Goods Sold	*	Days in Period
	=	0	/	0	*	365 / 2
	=	N/A

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Medincell's Inventory Turnover for the quarter that ended in Sep. 2023 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	0	/	0
	=	N/A

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Medincell's Inventory to Revenue for the quarter that ended in Sep. 2023 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	0	/	6.985
	=	0.00

Medincell Change In Inventory Related Terms

Thank you for viewing the detailed overview of Medincell's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

Medincell (XPAR:MEDCL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medincell SA (XPAR:MEDCL) » Definitions » Change In Inventory

Comparable Companies

Traded in Other Exchanges

MEB:Germany

Address

3 rue des Freres Lumiere, Jacou, FRA, 34830

Website

https://www.medincell.com

Medincell SA is a technology-based pharmaceutical firm, aims to optimise the efficiency of medical treatments and make them accessible geographically. The company's product portfolio uses BEPO-patented technology to develop controlled, long-acting injectable medical treatments for a number of therapeutic fields. The firm has a single operating segment: ongoing research and development on processes that use biodegradable polymers to enable the controlled and prolonged release of the active principles of drugs into the human body and animals by means of injection.

Medincell (XPAR:MEDCL) Headlines

No Headlines